ChondroFiller™ and the hip cartilage problem it targets

Patients often arrive at this point having been told their hip cartilage is worn — and wondering exactly what is going to be put into their joint. ChondroFiller™ is not a steroid, a painkiller, or a hyaluronic acid filler. It is a CE-marked Class III medical device: an acellular injectable hydrogel made from Type I collagen, manufactured by Meidrix Biomedicals GmbH in Germany. 'Acellular' means it contains no living cells — what it provides is a structural scaffold.

Once delivered into the hip joint, the collagen gel self-sets in situ within approximately three to five minutes, forming a protective cushioning layer that settles over the damaged articular surface. The mechanism is described as acellular matrix-induced chondrogenesis: the scaffold acts as a chemotactic matrix, recruiting the patient's own progenitor cells from the surrounding synovium and subchondral bone, and supports the body's own repair processes from within the defect site. Laboratory evidence from an ex vivo osteochondral study recorded a 2.4-fold increase in DNA content within the ChondroFiller scaffold by day 14, consistent with meaningful host cell recruitment.

The pathology it targets matters for patient selection. ChondroFiller is designed for isolated, focal Grade III or IV cartilage defects — the kind of localised chondral loss frequently associated with femoroacetabular impingement (FAI) or early-stage hip osteoarthritis, where surrounding cartilage remains largely intact. It is not indicated for diffuse, full-thickness articular cartilage loss or advanced osteoarthritis; published cohort data from Mazek et al. (2021) found that hip patients with pre-existing Tönnis grade 2–3 osteoarthritis had poor results following ChondroFiller treatment.

At Lincolnshire Hip, the procedure is delivered as an ultrasound-guided outpatient injection — no theatre, no surgical incision, and no general anaesthetic.

Patients most likely to benefit — and those who are not

The best evidence for patient selection comes from Mazek et al. (2021, Journal of Hip Preservation Surgery, n=26): 17 of 21 patients followed for up to five years reported good or excellent outcomes. Those patients shared a consistent profile — typically under 50, with an isolated focal acetabular cartilage defect greater than 2 cm², a well-aligned joint, intact surrounding ligaments, and femoroacetabular impingement (FAI) as the upstream cause of their chondral damage. FAI is among the most common reasons focal cartilage loss develops in the hip in active adults, and patients who carry that diagnosis often arrive already partway through the clinical picture ChondroFiller is designed to address.

The same cohort drew a sharp contraindication line. Patients with Tönnis grade 2–3 osteoarthritis — a radiological measure of moderate-to-severe joint degeneration visible on imaging — had poor results. Where cartilage loss is diffuse rather than focal, or where the joint architecture has deteriorated across a broader area, a collagen scaffold placed over one site cannot correct the underlying problem.

The 70–85% good/excellent outcome range cited in published literature is specific to that narrow, well-defined patient group. It does not transfer to patients with more advanced disease, and applying it indiscriminately would overstate the likely benefit for a significant proportion of people considering the procedure.

Confirming which side of that line a patient sits on requires imaging review and a clinical assessment. Tönnis grading, defect size, joint alignment, and ligament integrity interact in ways that symptoms alone cannot reveal. At Lincolnshire Hip, suitability assessment with Professor Paul Lee in Grantham or Sleaford addresses precisely those variables before any injection is planned.

Why the hip joint requires ultrasound guidance

The hip is not a joint that forgives imprecision. Sitting deep beneath several centimetres of muscle, fat, and connective tissue, it cannot be reliably accessed by feel or anatomical landmark alone — and the consequences of misdirection are not merely wasted product. Unguided ('blind') anterior-approach hip injections miss the target in up to 30% of cases, owing to the natural variation in body composition and joint anatomy between patients.

The anatomical hazard that makes this especially significant is the femoral neurovascular bundle — the femoral artery, vein, and nerve — which runs in close proximity to the anterior hip joint capsule, precisely where a needle approaching from the front must travel. Placing a needle without real-time imaging in this region carries a genuine risk of vascular or nerve contact that goes well beyond the inconvenience of an inaccurate injection.

Ultrasound guidance removes that uncertainty. With the patient lying on their back, the clinician applies a probe over the anterior hip and generates a live cross-sectional image showing the bony contour of the femoral head, the overlying soft-tissue layers, and the joint space. As the needle advances, its tip appears on screen as a bright echogenic point, allowing continuous real-time tracking. The clinician confirms the needle has entered the joint capsule before any gel is released — watching, not estimating.

The lateral short-axis approach used in image-guided hip procedures is specifically associated with near-zero vascular complication rates; in a published series of 276 hip arthrograms, 96.8% were graded Excellent or Good with no vascular complications recorded.

For ChondroFiller specifically, precise placement is not simply a safety measure — it is a functional requirement. Collagen gel deposited outside the joint space will not self-set over the cartilage defect, will not form a structural scaffold, and will not recruit the progenitor cells needed to support repair. The mechanism depends entirely on the gel arriving at the right site.

The injection appointment, step by step

The entire appointment takes place in an outpatient clinic — no theatre admission, no general anaesthetic, no overnight stay. Most patients are in and out within an hour.

Before the needle is introduced

The patient lies flat on their back on the treatment table. The clinician applies ultrasound gel and positions the probe over the front of the hip to review the anatomy and confirm the precise entry point — mapping the bony contour of the femoral head, the joint space, and the surrounding soft-tissue layers before any needle is introduced.

Once the target is confirmed, the hip area is cleaned thoroughly with antiseptic solution and sterile draping is applied around the site, following standard aseptic technique. A small volume of local anaesthetic is then injected into the skin and the deeper soft tissues beneath it. Most patients notice a brief stinging as the anaesthetic goes in, after which the area numbs; the main procedure is typically experienced as a feeling of pressure rather than sharp pain.

Needle placement and gel delivery

With local anaesthesia established, a fine-gauge cannula — typically G20 or G21 — is advanced through the anaesthetised tissue under continuous live ultrasound imaging. The needle tip is visible on screen in real time as a bright echogenic point; the clinician tracks it throughout and confirms it has entered the joint capsule before any gel is released. The ChondroFiller collagen scaffold is then delivered in a precisely controlled volume directly over the focal cartilage defect.

Once inside the joint, the gel begins setting against the worn articular surface, forming a protective cushioning layer and providing a structural matrix that draws the patient's own progenitor cells into the collagen scaffold.

After the needle is withdrawn

Firm pressure is applied immediately over the puncture site to prevent haematoma formation, and a sterile dressing is placed. Patients are advised to take a short course of NSAIDs for seven days to manage any post-procedure inflammation, and leave the clinic with a discharge letter detailing aftercare instructions.

Recovery after the injection — the first days and weeks

Going home is straightforward — most patients leave the clinic within an hour, the same day, without hospital admission. The practical arrangements that matter most are those made before the appointment, not after.

Transport. Driving is not appropriate immediately after the procedure. The local anaesthetic will still be active, and the hip needs protection from the loading that operating pedals places on the joint. Patients travelling from rural parts of Lincolnshire should arrange a driver well in advance.

Protected weight-bearing — and why it matters mechanically. A period of crutch-assisted or protected weight-bearing, typically one to six weeks, is the single most clinically important adjustment in the days that follow. This is not general caution. A 2024 biomechanical study confirmed that the ChondroFiller scaffold lacks initial mechanical stability under full joint loading; placing full weight through the hip before the gel has integrated carries a genuine risk of displacing the scaffold before it has had the chance to set and draw the patient's own progenitor cells into the collagen matrix. The exact duration will be agreed with the treating clinician based on individual factors.

What to expect as recovery progresses. Matrix-induced chondrogenesis is a gradual biological process. Some discomfort in the days immediately following the injection is expected and is not a sign that treatment has failed. Meaningful improvement — reflected in published series by Harris Hip Score gains averaging around 33 points, and MOCART MRI regeneration scores in the 70–87 range — typically emerges over weeks to months as the scaffold matures and host cell activity develops, rather than in the immediate aftermath of the appointment.

Getting a ChondroFiller hip injection in Lincolnshire

ChondroFiller hip injections are available at Lincolnshire Hip's two clinic sites in Grantham and Sleaford, led by Professor Paul Y. F. Lee — a consultant with specific expertise in hip cartilage preservation. No GP referral is required; patients from across Lincolnshire and the wider non-London catchment can contact the service directly.

Funding. ChondroFiller is not available on the NHS, and standard private medical insurance — including Bupa and AXA — does not currently cover it. Access is on a self-funded basis; the UK package starts from £3,000 and includes the consultation, ultrasound scan, the ChondroFiller product, the injection itself, intravenous antibiotic cover, and a six-week follow-up appointment.

The first appointment. Before any treatment is booked, a clinical assessment reviews existing imaging, confirms suitability, and maps out the most appropriate pathway — whether a ChondroFiller injection, another cartilage preservation option, or a combination approach. Factors such as defect size, joint alignment, and treatment goals are all weighed at that stage.

Lincolnshire Hip is part of the MSK Doctors group; patients leave the assessment with a personalised recommendation rather than a single fixed plan.

1. [1] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002